Theranexus
Latest round
- Series A
Last raised
- Dec 2014
Total raised
- $3.1M
Investors
- 4
About Theranexus
Theranexus was founded in 2014 in Lyon, France, and specializes in the treatment of rare neurological disorders.Theranexus specializes in innovative treatment solutions for rare neurological diseases, with its lead clinical candidate targeting Batten disease, a severe neurodegenerative disorder. The end users of its products include healthcare professionals, institutions specializing in neurology, and patients.9 for 2022. The company is focusing on introducing new products to address rare neurological conditions, including Batten disease, while also exploring opportunities for expansion into new markets across Europe and North America.
Who invested in Theranexus
4 investors across 1 round
See all investors in Theranexus
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 16, 2014
Amount
$3.1M
Investors
Questions about Theranexus
Who invested in Theranexus?
Theranexus has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Theranexus raised?
Theranexus has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Theranexus last raise money?
Theranexus's most recent round on record is a Series A, in Dec 2014.
What does Theranexus do?
Theranexus was founded in 2014 in Lyon, France, and specializes in the treatment of rare neurological disorders.
Where is Theranexus headquartered?
Theranexus is headquartered in Lyon, France.
Which VCs invest in companies like Theranexus?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Theranexus's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Theranexus? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.